Require Prescription
Description:
Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease that can affect various parts of the body. It works by inhibiting the activity of B-lymphocyte stimulator (BLyS), a protein that promotes the survival of B cells, which are involved in the abnormal immune response in lupus.
Ingredients:
Active ingredient:
- Belimumab 400 mg per vial
Usage Instructions:
- Benlysta is administered intravenously by a healthcare professional.
- The typical initial dose is given in three infusions, 2 weeks apart.
- Maintenance doses are then given once every 4 weeks.
- The specific dosage and frequency will be determined by a healthcare provider based on the patient's condition and response to treatment.
Benefits:
- Reduces disease activity in systemic lupus erythematosus (SLE).
- Helps improve symptoms such as joint pain, fatigue, and skin rashes.
- May decrease the frequency of lupus flares.
- Can improve overall quality of life for lupus patients.
Precautions:
- Not recommended for use in patients with severe active infections.
- Monitor patients for allergic reactions during infusion.
- May increase the risk of infections; precautions should be taken to avoid exposure to infections.
- Inform healthcare providers of all medications and conditions before starting treatment.
- Common side effects include nausea, diarrhea, fever, and infusion reactions.
Storage Instructions:
- Store refrigerated between 2-8°C (36-46°F).
- Protect from light and do not freeze.
- Keep out of reach of children.
Manufacturer:
GlaxoSmithKline (GSK)
